Jane Street’s Immix Biopharma IMMX Stock Holding History

Jane Street’s Portfolio IMMX Stock Details IMMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35,164	Closed	-$320K	–	12303
2026 Q1	$320K	Sell	35,164 -131,968	-79%	-$969K	﹤0.01%	9099
2025 Q4	$874K	Buy	167,132 +152,162	+1,016%	+$626K	﹤0.01%	6405
2025 Q3	$31.3K	Buy	+14,970	New	+$35.9K	﹤0.01%	10448
2025 Q1	–	Sell	-17,523	Closed	-$38.6K	–	9970
2024 Q4	$38.6K	Buy	+17,523	New	+$32K	﹤0.01%	9035
2024 Q1	–	Sell	-14,922	Closed	-$103K	–	9608
2023 Q4	$103K	Buy	+14,922	New	+$67.6K	﹤0.01%	8565

Other funds holding IMMX

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street's IMMX Position: Q2 2026 in Review

Jane Street sold out of Immix Biopharma (IMMX) in Q2 2026, closing a stake of 35,164 shares — an estimated $320K sold.

Jane Street first reported a position in IMMX in Q4 2023 and held it in 5 quarters. The position peaked at $874K in Q4 2025. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

Jane Street reported no remaining Immix Biopharma position as of Q2 2026 after selling out during the quarter.
Jane Street sold 35,164 Immix Biopharma shares in Q2 2026, an estimated $320K.
Jane Street first reported a position in Immix Biopharma in Q4 2023 and held it in 5 quarters.
Jane Street's Immix Biopharma position peaked at $874K in Q4 2025.
109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.